Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11193326 | 0.90 | CYP2A13 (0.75) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL10513466 | 0.86 | CYP2A13 (0.65) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL27692704 | 0.82 | CYP2A13 (0.51) | CYP2A13KMT2AMEN1HRH3 | |
| SCHEMBL4108619 | 0.81 | CYP2A13 (0.69) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL22711364 | 0.81 | CYP2A13 (0.64) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL3311657 | 0.81 | CYP2A13 (1.00) | CYP2A13ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL111727 | 0.81 | CYP2A13 (0.64) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL2251851 | 0.81 | CYP2A13 (0.64) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL3730392 | 0.80 | CYP2A13 (0.67) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 | |
| SCHEMBL11201072 | 0.80 | CYP2A13 (0.62) | CYP2A13ALDH1A1CYP2C9KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101796038-B | Oxazole tyrosine kinase inhibitors | SAREUM LTD. (GB) | 2014-10-29 | — | — | CN | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| CN-1976706-B | FGFR3 inhibition and treatment of multiple myeloma | NOVARTIS VACCINES & DIAGNOSTIC | 2012-01-18 | — | — | CN | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| CN-101796038-A | Oxazole tyrosine kinase inhibitors | SAREUM LTD | 2010-08-04 | — | — | CN | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| CN-1976706-A | FGFR3 inhibition and treatment of multiple myeloma | CHIRON CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CYP2A13 292/4885ALDH1A1 276/4885CYP2C9 318/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | CYP2A13 290/4885ALDH1A1 152/4885CYP2C9 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.